Ocular Therapeutix (OCUL) Accumulated Depreciation (2013 - 2025)

Ocular Therapeutix's Accumulated Depreciation history runs 13 years deep, the most recent figure standing at $27.5 million for Q4 2025.

• On a quarterly basis, Accumulated Depreciation rose 16.45% year-over-year to $27.5 million in Q4 2025; TTM through Dec 2025 was $27.5 million, a 16.45% increase from a year earlier, with the FY2025 full-year figure at $27.5 million, up 16.45% from the prior year.
• Accumulated Depreciation rose to $27.5 million in Q4 2025 per OCUL's latest filing, from $23.6 million in the prior quarter.
• Across five years, Accumulated Depreciation topped out at $27.5 million in Q4 2025 and bottomed at $15.2 million in Q4 2021.
• The 5-year median for Accumulated Depreciation is $20.3 million (2023), against an average of $20.8 million.
• Across the five-year window, Accumulated Depreciation rose 18.93% in 2021 and increased 13.62% in 2022, its largest moves.
• Year by year, Accumulated Depreciation stood at $15.2 million in 2021, then climbed by 13.62% to $17.3 million in 2022, then rose by 17.26% to $20.3 million in 2023, then rose by 16.64% to $23.6 million in 2024, then rose by 16.45% to $27.5 million in 2025.
• Per Business Quant, the three latest OCUL Accumulated Depreciation figures stand at $27.5 million (Q4 2025), $23.6 million (Q4 2024), and $20.3 million (Q4 2023).